| Course | NU670 PMHNP Neuroscience and Psychopharmacology |
|---|---|
| Unit | Unit 8 |
| Paper type | Neuroplasticity brief |
| Length | About 490 words, 4 pages double-spaced |
| Format | APA 7 student paper |
| School | Purdue University Global |
| Program | MSN |
| Updated | September 2026 |
Free sample paper for NU670 Unit 8
Can an Antidepressant Rewire a Brain After Stroke? A Neuroplasticity Brief on Fluoxetine From Rat Visual Cortex to 3,127 Patients
[Student Name]
Purdue University Global
NU670: PMHNP Neuroscience and Psychopharmacology
Unit 8 Neuroplasticity Brief
[Instructor Name]
[Date]
The patient and family are composite; details are bracketed. The studies are real and cited.
The Question
Mr. [E.] is [66] and had a left middle cerebral artery stroke [nine] days ago. He has weakness of his right arm and leg, some difficulty finding words and a low mood; he cries when his grandchildren visit. His daughter found articles saying that fluoxetine, an antidepressant, helps the brain rewire itself after a stroke. She asked whether he should start it now, to help both his mood and his arm.
Tier One: Plasticity in Animals
The idea has a real basis in laboratory work. In adult rats, whose visual cortex has normally lost the flexibility of early life, chronic fluoxetine restored ocular dominance plasticity and helped recover vision in animals with experimentally induced amblyopia. The effect came with reduced inhibition within the cortex and higher levels of brain-derived neurotrophic factor, and it was blocked when diazepam was given to the cortex (Maya Vetencourt et al., 2008). This suggested that an antidepressant could reopen a window of plasticity in an adult brain, which is exactly the claim the daughter read.
Tier Two: A Small Positive Trial
The FLAME trial tested the idea in people. [118] patients with ischemic stroke and moderate to severe motor weakness were randomized to fluoxetine [20] mg or placebo for three months, starting [5 to 10] days after the stroke, with physiotherapy for all. Motor scores improved significantly more with fluoxetine, by about [34] points against [24] on the Fugl-Meyer scale at day [90] (Chollet et al., 2011). It was a careful trial, but small.
Tier Three: A Large Negative Trial
FOCUS was designed to settle the question. In [3,127] patients at [103] UK hospitals, fluoxetine [20] mg daily for six months did not improve functional outcome on the modified Rankin Scale compared with placebo. Fluoxetine did reduce new depression, [13.4] percent against [17.2] percent, but it also increased bone fractures, [2.9] percent against [1.5] percent, and the authors concluded that routine use to prevent depression or promote recovery was not supported (Dennis et al., 2019).
The plasticity story held in rats and in a small trial, and then did not hold in the trial large enough to answer the question.
What I Told the Family
Fluoxetine should not be started to help his arm recover; the largest trial found no benefit to function and a higher risk of fractures. His mood is a separate question. If his low mood persists and meets criteria for depression, an antidepressant is reasonable, with the fracture risk weighed and discussed, and fluoxetine is one option among several. For his arm, the treatment with the strongest support is intensive rehabilitation, which is already underway.
References
Chollet, F., Tardy, J., Albucher, J.-F., Thalamas, C., Berard, E., Lamy, C., Bejot, Y., Deltour, S., Jaillard, A., Niclot, P., Guillon, B., Moulin, T., Marque, P., Pariente, J., Arnaud, C., & Loubinoux, I. (2011). Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): A randomised placebo-controlled trial. The Lancet Neurology, 10(2), 123-130. https://doi.org/10.1016/S1474-4422(10)70314-8
Dennis, M., Mead, G., Forbes, J., Graham, C., Hackett, M., Hankey, G. J., House, A., Lewis, S., Lundström, E., Sandercock, P., Innes, K., Williams, C., Drever, J., Mcgrath, A., Deary, A., Fraser, R., Anderson, R., Walker, P., Perry, D., . . . Hungwe, R. (2019). Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): A pragmatic, double-blind, randomised, controlled trial. The Lancet, 393(10168), 265-274. https://doi.org/10.1016/S0140-6736(18)32823-X
Maya Vetencourt, J. F., Sale, A., Viegi, A., Baroncelli, L., De Pasquale, R., O'Leary, O. F., Castrén, E., & Maffei, L. (2008). The antidepressant fluoxetine restores plasticity in the adult visual cortex. Science, 320(5874), 385-388. https://doi.org/10.1126/science.1150516
The Purdue Global NU670 Unit 8 instructions
The Unit 8 brief asks you to explain a neuroplasticity claim linked to a psychotropic drug and to evaluate it for a clinical decision. Prompts usually want the mechanism described, the evidence arranged from laboratory to clinical studies, and a conclusion that answers a specific question. A brief of two to three pages is typical, so every paragraph must earn its place. Graders reward briefs that show where a claim holds and where it fails as studies move closer to patients. Citations are expected for each tier, and the final answer should be written so that a patient or family member could understand it and act on it without further explanation.
How the NU 670 Unit 8 example is put together
The brief opens with the family's question and the patient's deficits nine days after a left middle cerebral artery stroke. Tier one describes the rat visual cortex study, its reduced cortical inhibition and raised neurotrophic factor, and why it inspired the claim. Tier two reports FLAME's design and the difference in motor scores at day 90. Tier three reports FOCUS: no difference in function, fewer cases of new depression and more fractures, with the authors' conclusion. A highlighted sentence sums up how the claim weakened as the studies grew. The last section gives the family separate answers for the arm and the mood, pointing to rehabilitation for recovery.
NU670 Unit 8 rubric: what earns full points
A neuroplasticity brief in this course is usually graded on accuracy, appraisal across levels of evidence, relevance to the question, clarity for the audience and use of sources. Accuracy is checked on each study's design and results. The appraisal row rewards a brief that explains why a small positive trial and a large negative one can both be correct and which should guide practice. Relevance scores when every tier is tied back to the patient's decision. Clarity points go to plain language that a family could follow. Sources should include the original trials, not reviews of them, so the grader can check each number against the paper.
NU670 Unit 8 help from the desk
Students often stop at the animal evidence and present it as though it applied to patients. Another frequent error is citing the small positive trial without the large negative one that followed. Some briefs merge two separate questions, recovery of function and treatment of depression, into one answer. Others ignore the fracture risk reported in the larger trial. A brief that uses technical terms throughout loses the family it was written for. And leaving out what does help recovery, in this case intensive rehabilitation, turns a careful appraisal into a simple no without offering the family a plan. Check each number against its trial before submitting, since briefs are short enough that a single wrong figure stands out.
Get an NU670 Unit 8 example written to your instructions
Pass along the Unit 8 prompt your NU670 section set, with its rubric, and name the drugs involved if the prompt leaves that open. We write the first brief free to those instructions, back in 24-48h, with a timeline for each drug, the plasticity account traced link by link, and every mechanistic claim labeled with the species and design behind it. The paper above is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document.
More NU670 papers and MSN samples
- NU670 Unit 1: Trauma and the Hippocampus Post
- NU670 Unit 2: Rumination and the Default Mode Network
- NU670 Unit 3: Stress Physiology and Early Adversity
- NU670 Unit 4: Evidence Table, Inflammation
- NU670 Unit 5: Depression Biotypes Seminar Reflection
- NU670 Unit 6: Dopamine Pathways and Haloperidol
- NU670 Unit 7: Mood Stabilizer Drug Class Explainer
- NU670 Unit 9: Study Critique
- NU670 Unit 10: Developmental Neuroscience Paper
- NU657 Unit 8: Family Meeting Summary, Severe TBI
- NU656 Unit 8: AKI From Abdominal Compartment Syndrome
- NU655 Unit 8: Transfer Summary After TEN
- NU654 Unit 8: Serious Illness Summary, ALS
NU670 Unit 8 questions, answered
Is the BDNF hypothesis of depression still accepted?
It remains influential but has been revised repeatedly. Rodent studies consistently show antidepressants raising BDNF signaling, while human evidence relies largely on blood measures and postmortem tissue, which are indirect. Present it as a leading framework with strong animal support and partial human support, and note where the field has moved toward network and synapse-level accounts.
Where can I find a free NU670 Unit 8 sample paper?
The complete NU670 Unit 8 neuroplasticity brief is on this page, with the family's question, the three tiers of evidence and the advice given for his arm and his mood, plus three references. A brief on a different plasticity claim can be requested.
Does fluoxetine help recovery after stroke in NU670 Unit 8?
The FLAME trial of 118 patients found better motor scores with fluoxetine, but the FOCUS trial of 3,127 patients found no improvement in functional outcome at six months. The brief follows FOCUS and advises against starting fluoxetine to aid recovery.
What did FOCUS find about depression in NU670 Unit 8?
Fluoxetine reduced new depression by six months, 13.4 percent against 17.2 percent with placebo, but bone fractures rose from 1.5 percent to 2.9 percent. The authors did not support routine use to prevent depression after stroke.
Why does NU670 Unit 8 start with a rat study?
Because the claim the family read began there. Chronic fluoxetine reopened plasticity in the adult rat visual cortex and helped recovery from induced amblyopia, which suggested an antidepressant could make an adult brain more changeable. The brief then shows how that idea fared in human trials.